Key result
The CHIEF study successfully enrolled 13,542 high-risk hypertensive patients in China to compare amlodipine plus telmisartan versus amlodipine plus diuretics, with well-matched baseline characteristics.
Why the study?
Does amlodipine plus telmisartan compared to amlodipine plus diuretics reduce the composite of non-fatal stroke, non-fatal myocardial infarction, and cardiovascular death in high-risk hypertensive patients?
RCT (n=13,542)
PROBE (prospective, randomized, open-labelled, blinded endpoint evaluation)
2x2 factorial design
Yes
Does amlodipine plus telmisartan compared to amlodipine plus diuretics reduce the composite of non-fatal stroke, non-fatal myocardial infarction, and cardiovascular death in high-risk hypertensive patients?
The CHIEF study is a large-scale randomized controlled trial designed to evaluate whether amlodipine plus an ARB is superior to amlodipine plus a diuretic in reducing cardiovascular events in high-risk Chinese hypertensive patients.
Large RCT now positioned to compare ARB- vs diuretic-based therapy in high-risk hypertension; extends combination regimen evidence to East Asian populations.
The Chinese Hypertension Intervention Efficacy Study (CHIEF) is a multi-centre randomized controlled clinical trial comparing the effects of amlodipine+angiotensin II receptor blocker and amlodipine+diuretics on the incidence of cardiovascular events, represented as a composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death events in high-risk Chinese hypertensive patients. The study also evaluates the long-term effects of lipid-lowering treatment and lifestyle modification. From October 2007 to October 2008, 13,542 patients were enrolled into the study in 180 centres in China. Patients will be followed up for 4 years. There was no difference in baseline characteristics between the two blood pressure arms.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2010) conducted an RCT in Hypertension (n=13,542). Amlodipine + telmisartan vs. Amlodipine + amiloride/hydrochlorothiazide was evaluated on Composite of non-fatal stroke, non-fatal myocardial infarction, and cardiovascular death. The CHIEF study successfully enrolled 13,542 high-risk hypertensive patients in China to compare amlodipine plus telmisartan versus amlodipine plus diuretics, with well-matched baseline characteristics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: